Background: When patients have HIV RNA suppressed to <50 copies/ml on current treatment, switching to darunavir (DRV)/ritonavir (DRV/r) monotherapy could prevent the development of resistance to other drug classes. Methods: In the MONET trial, 256 patients with HIV RNA<50 copies/ml on current highly active antiretroviral therapy (57% with protease inhibitors [PIs] and 43% with non-nucleoside reverse transcriptase inhibitors) and no history of virological failure were randomized to DRV/r 800/100 mg once daily, either as monotherapy (monotherapy arm) or with two nucleoside reverse transcriptase inhibitors (NRTIs; triple therapy arm). All samples with HIV RNA≥50 copies/ml were genotyped, and a virtual phenotype was calculated (VircoType HIV-1 assays; Virco BVBA, Mechelen, Belgium). Results: A total of 63 patients had ≥1 HIV RNA result ≥50 copies/ml, of whom 38 were successfully genotyped. Most HIV RNA increases were transient and in the range of 50-200 copies/ml. Overall, 36 of the 38 (95%) successfully genotyped patients showed no International AIDS Society-USA major PI mutations, DRV mutations or NRTI mutations. Two patients showed some evidence of PI resistance during transient HIV RNA elevations: one patient in the monotherapy arm had a single DRV mutation (L33F) when HIV RNA was 63 copies/ml (the virus was phenotypically sensitive to DRV [fold change 0.8]) and one PI pretreated patient taking tenofovir disoproxil fumarate/emtricitabine/DRV/r had re-emergence of preexisting NRTI (M184V) and PI (V82I and L90M) mutations after a short treatment interruption (this virus remained phenotypically sensitive to DRV/r). Both patients showed sustained HIV RNA suppression to week 48 remaining with the same treatment. Conclusions: Emergence of drug resistance after changing a suppressive triple antiretroviral therapy to DRV/r with or without nucleoside analogues is uncommon.
The emergence of antiretroviral drug resistance could lead to virological failure and could limit a patient's future treatment options. Current treatment guidelines recommend first-line use of two nucleoside analogues with either a non-nucleoside reverse transcriptase inhibitor (NNRTI) or a ritonavir-boosted protease inhibitor (PI) [1, 2] . However, the choice of combination treatment can affect the risk of drug resistance at treatment failure. In a recent meta-analysis of clinical trials, 53% of patients who failed first-line NNRTI-based treatment had NNRTI resistance mutations, whereas only 0.9% of patients who failed boosted PI-based highly active antiretroviral therapy (HAART) had primary PI mutations [3] . Patients who failed first-line NNRTI-based HAART were also more likely to show the M184V mutation (35%), compared with patients failing firstline boosted PI-based HAART (21%). Similar results have been demonstrated in cohort studies [4, 5] .
The PI darunavir has a high genetic barrier and relatively long terminal elimination half-life with ritonavir (15 h) [6] . In the ARTEMIS trial of first-line treatment with darunavir/ritonavir 800/100 mg once-daily plus two nucleoside analogues, there were 31 patients successfully genotyped after showing rebound in HIV 
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RNA ≥50 copies/ml: none of these 31 patients developed a primary International AIDS Society (IAS)-USA PI mutation, whereas 2 (6.5%) developed the M184V mutation [7] . Although this low prevalence of resistance was seen when darunavir/ritonavir was used in combination with two nucleoside analogues, it is unknown whether the resistance profile would be the same if darunavir/ritonavir is used as a monotherapy.
In the MONET trial, 256 patients with HIV RNA levels <50 copies/ml on antiretroviral treatment and no history of virological failure were randomized to receive darunavir/ritonavir 800/100 mg once daily, either as monotherapy (monotherapy arm) or in combination with two nucleoside analogues (triple therapy arm) [8] .
In the primary efficacy analysis, 86.2% of patients in the monotherapy arm showed HIV RNA<50 copies/ml by week 48 versus 87.8% of patients in the triple therapy arm. This result demonstrated non-inferior antiretroviral efficacy for the monotherapy arm compared to the triple therapy arm. The aim of this analysis was to measure the prevalence of drug resistance during episodes of transient or sustained HIV RNA viraemia in the MONET trial.
Methods
The MONET trial recruited 256 patients who had HIV RNA levels <50 copies/ml on a stable triple antiretroviral regimen for at least 24 weeks, and no history of virological failure since first starting antiretrovirals (defined as two HIV RNA determinations >500 copies/ ml). This trial has been described in detail elsewhere [8] . Briefly, patients were randomized to receive darunavir/ ritonavir 800/100 mg once daily, either as monotherapy (monotherapy arm) or with two nucleoside analogues (triple therapy arm). The nucleoside analogues used during the MONET trial were selected by the investigators and could be changed either at screening or during the trial. Because pretrial stored samples were not available for most patients, it was not possible to determine the baseline genotype in many cases; therefore, resistance mutations observed during the trial might have been pre-existing.
Patients attended study visits at screening, baseline and weeks 4, 12, 24, 36 and 48. Any patient with an HIV RNA result ≥50 copies/ml attended a confirmation visit within 2 weeks for repeated testing of HIV RNA, drug resistance and plasma drug levels. If a patient had two consecutive HIV RNA levels ≥50 copies/ml, investigators could intensify or change antiretrovirals. In addition, all patients were followed up to week 48.
Plasma HIV RNA was measured using the Roche Amplicor HIV-1 Monitor assay (version 1.5; Roche Molecular Systems, Branchburg, NJ, USA). Viral genotypic tests were performed using standard VircoType HIV-1 assays (Virco BVBA, Mechelen, Belgium). Genotypic drug resistance was assessed for all patient samples with HIV RNA concentrations ≥50 copies/ml up to September 2009. There is limited success of genotyping at low HIV RNA levels [9] . Virtual phenotyping was used to assess phenotypic sensitivity. Also, the number of patients with either IAS-USA major or minor PI mutations, darunavir mutations, M184V or other nucleoside reverse transcriptase inhibitor (NRTI) mutations [10] was analysed by treatment arm.
Genotypic mutations were defined as follows: darunavir mutations included V11I, V32I, L33F, I47V, The percentage of patients with each mutation was calculated from the number of patients with ≥1 successful genotype. The analysis assumed a worst case scenario: if any one of a patient's samples showed a mutation, the patient was assumed to have this mutation, even if other samples showed wild-type virus.
Minor IAS-USA PI mutations: comparison with the Stanford University HIV Drug Resistance Database
The VircoType HIV-1 assays (Virco BVBA) report lists all deviations in amino acid sequence from the reference HXB2 strain. Some of these deviations can be major mutations, as listed above, whereas other minor IAS-USA PI mutations might be an indication of drug resistance; however several IAS-USA minor PI mutations are commonly found in samples from patients never treated with PIs [11]. These mutations might therefore reflect the background diversity of HIV protease structure, rather than treatment-emergent drug resistance. The Stanford University HIV Drug Resistance Database includes samples from a range of HIV subtypes [11]. The database can be searched to calculate the percentage of PI-naive patients who have changes from the reference HXB2 strain at various positions. For example the L63P mutation is seen in 55% of HIV subtype B samples from patients never treated with PIs.
The prevalence of each deviation from the reference HXB2 strain was summarized in the monotherapy and triple therapy arms of the MONET trial, and compared with the reference Stanford database: this included 7,601 HIV subtype B samples taken from PI-naive patients. The prevalence of these minor IAS-USA PI mutations was compared between the monotherapy and triple therapy arms of the MONET trial and with the Stanford database. The prevalences of changes from HXB2 were presented with associated 95% confidence intervals: non-overlapping 95% confidence intervals are an approximate measure of differences between groups. The χ 2 test with Yate's correction for differences in proportions were used to analyse differences between the two treatment arms of the MONET trial and between either treatment arm and the Stanford database. Table 1 shows a summary of the key baseline characteristics from the MONET trial. The patients were 78% male and 92% Caucasian, with a median CD4 + T-cell count of 575 cells/µl. To be included in the trial, patients needed to have no history of virological failure on antiretroviral treatment and HIV RNA levels <50 copies/ml at screening. There was a longer median duration of prior antiretroviral treatment in the monotherapy arm (7.4 years) compared with the triple therapy arm (6.4 years). There was a diversity of prior antiretroviral treatment, ranging from patients still on their first randomized treatment for 18 months to patients with ≥10 years of antiretroviral treatment. At screening, 35% of patients in the monotherapy arm and 48% in the triple therapy arm were still taking their first antiretroviral combination treatment. In the monotherapy arm, 77% of patients had received ≥1 PI versus 72% of patients in the triple therapy arm. After 48 weeks, 86.2% of patients in the monotherapy arm and 87.8% of patients in the triple therapy arm had HIV RNA<50 copies/ml in the primary analysis (per protocol, switch equals failure). There were 7 patients with two HIV RNA levels ≥50 copies/ml in the triple therapy arm versus 11 in the monotherapy arm. Table 2 shows a summary of the genotypic data from the trial. In the monotherapy arm, 39/127 (31%) patients had ≥1 HIV RNA result ≥50 copies/ml, versus 31/129 (24%) patients in the triple therapy arm; however most of these were transient elevations in HIV RNA in the range of 50-400 copies/ml. Retesting of 28 HIV RNA samples with HIV RNA levels of 50-100 copies/ml showed HIV RNA results <50 copies/ml in 78%.
Results
Genotypes were available for 38/80 (48%) patients with ≥1 HIV RNA result ≥50 copies/ml. Overall, 36 (95%) of these 38 patients showed no major PI mutations, darunavir mutations or NRTI mutations. There was one patient in each treatment arm who showed genotypic resistance to PIs or nucleoside analogues, both harbouring clade B viruses. Figures 1 and 2 show HIV RNA profiles over time for these two patients.
One PI pretreated patient in the triple therapy arm had a single genotype showing resistance to lamivudine (M184V) and to PIs (V82I/T and L90M). This genotype was seen when the HIV RNA level was 78 copies/ ml, after a short interruption of treatment. However the virus was phenotypically sensitive to darunavir/ritonavir (fold change 1.2). All subsequent visits showed HIV RNA levels <50 copies/ml. The retrospective analysis of a stored HIV RNA sample for this patient, obtained during a low-level transitory viral rebound (483 copies/ml) while taking zidovudine plus lamivudine plus nelfinavir 2 years before her inclusion in the MONET trial, showed that these mutations were already present before the patient started treatment in the trial. Summary results are shown in Figure 1 .
One PI pretreated patient in the monotherapy arm had a single darunavir mutation (L33F) when the HIV RNA level was 63 copies/ml at a single visit (week 12). However the virus was phenotypically sensitive to darunavir (fold change 0.8) and HIV RNA was suppressed <50 copies/ml for this patient for all subsequent visits to week 48. There was no prebaseline sample available to determine whether this mutation was pre-existing. Summary results are shown in Figure 2 .
As shown in Table 3 , the prevalence of minor IAS-USA PI mutations was very similar in the monotherapy and triple therapy arms of the MONET trial. There were 15 amino acid positions in the protease gene where ≥1 patient showed a minor IAS-USA PI mutation. The percentage of genotyped patients with minor IAS-USA PI mutations was higher in the triple therapy arm for 11 of these positions, and higher for the monotherapy arm for 5 positions. There was no systematic trend for the overall prevalence of minor IAS-USA PI mutations to be higher in either arm of the MONET trial; however these prevalence estimates had wide 95% confidence intervals, given the small number of genotypes evaluated in each treatment arm of the MONET trial. No changes were seen in either group for the following positions: L24I, E34Q, F53L/Y, G73A/C/S/T, N83D and I85V. There were no significant differences between the two treatment arms for any of the minor IAS-USA PI mutations.
The overall prevalence of each minor IAS-USA PI mutation was then compared to the prevalence in the Stanford database of 7,601 samples from PI-naive patients (Table 3) . These minor IAS-USA PI mutations had a wide range of prevalence in the Stanford database, ranging from 0% (for example, with Q58E) to 55% (for L63P). For most of the positions evaluated, the 95% confidence intervals of the prevalence estimates were overlapping between the PI-naive samples in the Stanford database and the two arms of the MONET trial. In the two treatment arms of the MONET trial, the K20I/R/M/T/V mutation had a higher prevalence compared with the Stanford database (P<0.01). In the triple therapy arm, there was a higher prevalence of the M36ILV (P<0.01), Q58E (P<0.01) and I62V (P=0.028) mutations, relative to the Stanford database. In the monotherapy arm, there was a higher prevalence of the L33IV (P<0.01), H69K (P=0.018) and I93L (P=0.016) mutations relative to the Stanford database.
In the MONET trial, 90% of the genotypes obtained were from clade B virus. The above analysis was repeated, excluding patients with non-clade B virus, and similar results were found (FP et al., data not shown).
Discussion
In the MONET trial of darunavir/ritonavir monotherapy versus darunavir/ritonavir plus two nucleoside analogues, elevations in HIV RNA were mainly transient, and not associated with drug resistance. Only 2 of 36 genotyped patients (one per treatment arm) showed some evidence of genotypic drug resistance during short-term elevations in HIV RNA: both remained phenotypically sensitive to darunavir, and both patients had sustained suppression of HIV RNA to <50 copies/ml during the trial. The patient with drug resistance in the triple therapy arm was found to have pre-existing resistance to PIs and nucleoside analogues. The patient in the monotherapy arm had a single darunavir mutation (L33F) but it is unknown whether this was present before the trial.
In this analysis of the MONET trial, every sample with HIV RNA≥50 copies/ml was tested for drug resistance. Often, drug resistance is only tested for patients with sustained elevations in HIV RNA>400-1,000 copies/ml, for example, in the recently published STARTMRK trial of first-line raltegravir [11], the Gilead 934 trial of first-line efavirenz based HAART [12] or the MERIT trial of first line maraviroc [13] . If only the samples with HIV RNA>400 copies/ml had been tested in the MONET trial, no treatment emergent drug resistance would have been detected. Other studies have evaluated genotyping for samples with HIV RNA levels of 50-400 copies/ml [7] , but genotyping has limited success at these HIV RNA levels [9] . It must also be noted that when testing resistance in samples with low HIV RNA levels, there could be a possibility of sampling error because of the low number of HIV RNA copies/ml, and using population genotyping might have missed lower frequency variants or selected a random variant not necessarily representative of the predominant strains.
In the MONET trial, the patients had to have a history of HIV RNA levels <50 copies/ml on antiretroviral treatment; therefore, it was not possible to determine whether any drug resistance detected was treatment emergent or pre-existing. The mean duration of prior treatment was 7 years, and many patients started antiretroviral treatment before drug resistance testing in treatment-naive patients became routine clinical practice. Previous virological failure exclusion criteria was defined per protocol as two previous HIV RNA determinations >500 copies/ml; thus, the only patients with the potential to measure drug resistance on treatment were patients with samples stored during lowlevel rebounds (<500 copies/ml), such as the patient in the triple therapy arm with re-emergence of pre-existing mutations, or protocol violators. The prevalence of minor IAS-USA PI mutations was similar in the two treatment arms of the MONET trial, and was comparable to the Stanford database of subtype B samples from PI-naive patients. There were some mutations that were seen more often in the MONET trial compared with the Stanford database (four mutations in the triple therapy arm and four in the monotherapy arm); however, because the MONET trial recruited mainly PI pretreated patients, there might have been evolution of the virus before the trial started and it is difficult to determine whether they were pre-existing or treatment emergent. Nevertheless, the absence of significant differences between the arms of the study does not support the hypothesis of a higher risk of emergence of resistance mutations with darunavir/ritonavir as compared with triple therapy.
Treatment with a single antiretroviral for patients with full HIV RNA suppression could improve tolerability, lower pill counts and costs and prevent resistance developing to other antiretroviral classes. However, a meta-analysis of previous clinical trials of PI monotherapy, mainly with lopinavir/ritonavir, has shown significantly greater rates of treatment failure for lopinavir/ritonavir monotherapy versus triple-drug combinations [14] . Despite this finding, the incidence of treatment emergent PI drug resistance during PI monotherapy has been very low [15] [16] [17] , and most patients with low-level viraemia on PI monotherapy can subsequently be resuppressed by intensifying treatment with nucleoside analogues [18] .
In the OK04 trial, the incidence of PI resistance in patients exposed to lopinavir/ritonavir monotherapy has been very low (0.7 per 100 patient-years) [19] . PI resistance development was not seen in the clinical trial ACTG 5201, in which patients received atazanavir/ ritonavir monotherapy. Interestingly, in ACTG 5201, PI resistance was not seen by population genotyping or by single genome sequencing [20] . By contrast with these findings, in the OREY trial, 2 out of 61 patients receiving atazanavir/ritonavir monotherapy who experienced virological failure rebounded with HIV isolates containing the N88S mutation in the protease gene [21] .
In other studies, resistance to PIs has been rare at failure, but NRTI resistance has been demonstrated [3] . The use of darunavir/ritonavir monotherapy could prevent the emergence of NRTI resistance, while maintaining the very low incidence of PI resistance at failure. Larger trials and longer-term follow-up are needed to confirm the results from this analysis. The French MONOI study has also shown no evidence for resistance to PIs for the three patients with HIV RNA levels >400 copies/ml while taking darunavir/ritonavir monotherapy [22] . The Medical Reseach Council PIVOT trial of PI monotherapy is currently enrolling patients and uses a primary end point of drug resistance at treatment failure.
In summary, the prevalence of resistance to PIs was low in the MONET trial of darunavir/ritonavir, with or without nucleoside analogues. This result is consistent with previous studies of darunavir/ritonavir given with nucleoside analogues in treatment-naive patients and with other studies of PI monotherapy.
